2
Registered trials
2
Recruiting
2
Unique sponsors
4
Unique IMPs
0
Commercial trials
Drug classes (ATC)
V
Various (ATC V)
1
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Monoclonal antibody (immune)
2 substances
Phase II:
2
Phase II
2 trials-
RecruitingAalborg University Hospital Academic(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE; FLUDEOXYGLUCOSE (18F)
-
RecruitingIntergroupe Francophone De Cancerologie Thoracique AcademicCEMIPLIMAB; FIANLIMAB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Aalborg University Hospital | Academic | 1 | Phase II | 1 |
| Intergroupe Francophone De Cancerologie Thoracique | Academic | 1 | Phase II | 1 |
New trials by year
2025
1
2026
1